IDiyas

For the Inventor, By the Inventor

Durban, South Africa

Melendran Pillay

USPTO Granted Patents = 13

Average Co-Inventor Count = 7.3

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:

goldMedal13 out of 3,201 
 
King Fahd University of Petroleum and Minerals
 patents

Years Active: 2023-2025

Loading Chart...
13 patents (USPTO):Explore Patents
1. 12227480 - 1-(2-(substituted phenyl)-2-oxoethyl)-4-methylpyridin-1-ium bromide as anti-tubercular agents (2025-02-18),
2. 12172973 - (E)-2-(3-Cyano-4-isobutoxyphenyl)-N'-(substituted benzylidene)-4-methylthiazole-5-carbohydrazides as anti-tubercular agents (2024-12-24),
3. 12145915 - (E)-2-(3-cyano-4-isobutoxyphenyl)-n'-(substituted benzylidene)-4-methylthiazole-5-carbohydrazides as anti-tubercular agents (2024-11-19),
4. 11998532 - Substituted 1,3,4-oxadiazole derivatives as anti-tubercular agents (2024-06-04),
5. 11981643 - Oxoimidazolidine derivatives as anti-tubercular agents (2024-05-14),
6. 11976076 - Substituted 7,8-dihydropyrimido[4,5-d]pyrimidines as anti-tubercular agents (2024-05-07),
7. 11976066 - Substituted 7-amino-3-(substituted benzoyl)indolizine-1-carboxylates as anti-tubercular agents (2024-05-07),
8. 11939294 - 1-(2-(substituted phenyl)-2-oxoethyl)-3,5-dimethylpyridin-1-ium bromides as antitubercular agents (2024-03-26),
9. 11938120 - Ethyl 2-substituted-1-(substitutedbenzoyl)-7-methylpyrrolo[1,2-a]quinoline-3-carboxylate derivatives as anti-tubercular agents (2024-03-26),
10. 11926627 - Substituted 7-methyl quinoline derivatives as antitubercular agents (2024-03-12),
11. 11919860 - 1-2(-(substituted phenyl)-2-oxoethyl)-4-(isopropoxycarbonyl)pyridin-1-ium bromides as anti-tubercular agents (2024-03-05),
12. 11912683 - (6-methyl-4-substitutedphenyl-2-oxo/thioxo-1,2,3,4-tetrahydropyrimidin-5-yl)(piperidin-1-yl)methanones as antitubercular agents (2024-02-27),
13. 11807640 - 7-isopropyl 1-ethyl/methyl 3-(substituted benzoyl)-2-substituted indolizine-1,7-dicarboxylates as anti-tubercular agents (2023-11-07),

Title: Melendran Pillay: Innovator in Anti-Tubercular Agents

Introduction

Melendran Pillay is a notable inventor based in Durban, South Africa. He has made significant contributions to the field of pharmaceuticals, particularly in developing anti-tubercular agents. With a total of 13 patents to his name, Pillay's work is recognized for its innovative approach to combating tuberculosis.

Latest Patents

Pillay's latest patents include the development of 1-(2-(substituted phenyl)-2-oxoethyl)-4-methylpyridin-1-ium bromide as anti-tubercular agents. This patent details novel derivatives of the compound, a method for synthesizing these compounds, a pharmaceutical composition that includes these compounds and a suitable carrier, as well as a method for using the compounds. These derivatives are particularly useful in the fight against tuberculosis. Another significant patent involves (E)-2-(3-Cyano-4-isobutoxyphenyl)-N'-(substituted benzylidene)-4-methylthiazole-5-carbohydrazides, which also serves as an anti-tubercular agent. This patent outlines the synthesis of arylhydrazones derivatives, their pharmaceutical composition, and methods of use.

Career Highlights

Melendran Pillay is affiliated with King Fahd University of Petroleum and Minerals, where he continues to advance his research in pharmaceuticals. His work has garnered attention for its potential impact on public health, particularly in regions where tuberculosis remains a significant concern.

Collaborations

Pillay has collaborated with notable colleagues, including Katharigatta N Venugopala and Mohamed A Morsy. These collaborations have contributed to the depth and breadth of his research, enhancing the development of effective anti-tubercular agents.

Conclusion

Melendran Pillay's innovative work in the field of pharmaceuticals, particularly in developing anti-tubercular agents, showcases his commitment to addressing critical health challenges. His contributions through numerous patents reflect his dedication to improving public health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…